Crystagen is sold as a short-peptide "bioregulator" from the Khavinson family and is marketed for immune-system research. This monograph is unusual: its most important finding is a negative one. Neither VialTalk's indexed research library nor PubMed contains a source that states Crystagen's amino-acid sequence. Its chemical identity therefore cannot be confirmed from the literature. What follows sets out what can be sourced, which is one ageing-spleen study, and what cannot.
Not established by available sources. The only peer-reviewed record found that names Crystagen is a 2014 Russian-language paper from the St. Petersburg Institute of Bioregulation and Gerontology [1]. Its English abstract calls Crystagen a "short peptide" but does not give its sequence, length or source tissue [1]. A PubMed search for "Crystagen" returns that paper and nothing else. Any vendor's stated sequence, tissue of origin or molecular weight for Crystagen should therefore be treated as an unverified vendor claim, not a literature fact, until a primary source is produced. This matters more than usual in this family. Activity in the Khavinson peptides is strongly sequence- and chirality-dependent: the mirror-image isomer of Thymogen has the opposite, immunosuppressive effect [3]. Mislabelling between short Khavinson peptides is also a known quality problem [2].
No Crystagen-specific mechanistic study was found. The family-level hypothesis is that ultrashort peptides enter cells and change gene expression in tissue-specific patterns set by their sequence [2]. That hypothesis cannot be applied to Crystagen in any testable way without a confirmed sequence. The one available abstract reports an effect on B-cells in ageing spleen tissue but describes no molecular pathway [1].
Human: none found. No human study, trial or case series of Crystagen was found.
Animal / tissue-level (model not stated in the abstract): one study. Chervyakova and colleagues compared four short peptides (Vilon, Thymogen, Crystagen and a peptide designated R-1) for immunoprotective effects in the ageing spleen [1]. According to the English abstract:
The full text of [1] is in Russian and was not reviewed. Species, model, group sizes and statistics are not available from the abstract, so the size and reliability of the effect cannot be judged.
Cell / in vitro: no Crystagen-specific in vitro study was found.
Very low. The record is:
Even the one positive signal (B-cell activation) comes with a reported limitation in the same sentence: no cell renewal in the ageing spleen [1]. Claims that Crystagen supports immunity in people are not backed by any source VialTalk could locate. This monograph is short because the evidence is thin.
Crystagen is grouped with the immune-oriented Khavinson peptides. The two in that group with defined sequences and a larger literature are Vilon (Lys-Glu) [2] and Thymogen (Glu-Trp) [3]. Those two show what a sourced identity looks like for this family. Even for them, the evidence is mostly preclinical and regionally concentrated [2][3]. Crystagen's record is substantially weaker than either.
Supplied as a lyophilized powder. Keep sealed vials refrigerated, dry and protected from light, and avoid repeated freeze-thaw cycling. No preparation guidance is given here.
With no literature sequence to check against, the COA is the only identity statement a researcher has. At minimum it should:
A COA that gives only the brand name "Crystagen" establishes nothing about identity. Because the family is prone to label swaps between short peptides [2], a stated sequence that differs between vendors or batches is a red flag in its own right. Sterility and endotoxin data are needed for any sterile-use research work.
[1] Chervyakova et al., Adv Gerontol 2014 — Immunoprotective activity of Vilon, Thymogen, Crystagen and R-1 in ageing spleen — https://pubmed.ncbi.nlm.nih.gov/28976144/
[2] VialTalk — Vilon research monograph — https://vialtalk.com/forum/peptide-research-library/vilon-research-monograph-khavinson-lys-glu-dipeptide
[3] VialTalk — Thymogen research monograph — https://vialtalk.com/forum/peptide-research-library/thymogen-research-monograph
Research-use note: This is an educational summary. Crystagen's amino-acid sequence could not be confirmed from any peer-reviewed source available to VialTalk, and its published evidence is limited to a single Russian-language ageing-spleen study whose model is not stated in the English abstract. There are no human data, and the compound is not approved for human use in any major jurisdiction known to VialTalk. Nothing here is medical advice or a usage recommendation.
